An Australian perspective on SADI-S/OADS: Excess weight loss and comorbidity improvement

Skye Marshall, Nova Jordaan, Jacobus Jordaan

Research output: Contribution to journalMeeting AbstractResearchpeer-review

12 Downloads (Pure)

Abstract

Background: The single anastomosis duodenal-ileal bypass with sleeve gastrectomy or one anastomosis duodenal switch (SADI-S/OADS) has been utilised as a treatment for obesity in Australia since 2016; however, the impact of SADI-S/OADS on health-related outcomes has not been reported in the Australian population. Objectives: To determine the effect of SADI-S/OADS on excess weight loss (EWL) and comorbidities in obese Australian adults. Methods: Retrospective cohort study. Adults were eligible if they attended SADI-S/OADS, with a minimum of 3-months follow-up. Results: 85 patients underwent SADI-S/OADS. Eligible patients were 44.7 (S.D. 10.9) years of age, 64.7% female, with an average follow-up of 10.7 months. At baseline the mean BMI was 47.0 (S.D. 9.1) and 30.3% had type II diabetes mellitus. At follow-up, EWL was 60.4%, where 58.8% achieved >50% EWL and 32% achieved >75% EWL. 80% of patients with type II diabetes achieved resolution. Total cholesterol to high density lipoprotein ratio improved from 4.5 (S.D. 1.1) mmol/L to 4.0 (S.D. 0.8) mmol/L (p=0.063). Conclusion: In Australia, initial results suggest that by an average of 10 months post-surgery, SADI-S/OADS is an effective treatment for obesity and results in a high rate of type II diabetes resolution with improvements to the lipid profile. Long-term follow-up will strengthen confidence in the efficacy of SADI-S/OADS for treating obesity in Australia.
Original languageEnglish
Article numberO-134
Pages (from-to)158
JournalObesity Surgery
Volume29
Issue numberS5
DOIs
Publication statusPublished - Aug 2019
Event24th International Federation for the Surgery of Obesity and Metabolic Disorders World Congress - Madrid, Spain
Duration: 3 Sep 20197 Sep 2019
Conference number: 24th
https://www.ifso2019.com/

Fingerprint

Gastrectomy
Comorbidity
Weight Loss
Type 2 Diabetes Mellitus
Obesity
HDL Cholesterol
Cohort Studies
Retrospective Studies
Lipids
Health
Therapeutics
Population

Cite this

Marshall, Skye ; Jordaan, Nova ; Jordaan, Jacobus. / An Australian perspective on SADI-S/OADS: Excess weight loss and comorbidity improvement. In: Obesity Surgery. 2019 ; Vol. 29, No. S5. pp. 158.
@article{0f1bedfc646b4579a065952fcb27b0ea,
title = "An Australian perspective on SADI-S/OADS: Excess weight loss and comorbidity improvement",
abstract = "Background: The single anastomosis duodenal-ileal bypass with sleeve gastrectomy or one anastomosis duodenal switch (SADI-S/OADS) has been utilised as a treatment for obesity in Australia since 2016; however, the impact of SADI-S/OADS on health-related outcomes has not been reported in the Australian population. Objectives: To determine the effect of SADI-S/OADS on excess weight loss (EWL) and comorbidities in obese Australian adults. Methods: Retrospective cohort study. Adults were eligible if they attended SADI-S/OADS, with a minimum of 3-months follow-up. Results: 85 patients underwent SADI-S/OADS. Eligible patients were 44.7 (S.D. 10.9) years of age, 64.7{\%} female, with an average follow-up of 10.7 months. At baseline the mean BMI was 47.0 (S.D. 9.1) and 30.3{\%} had type II diabetes mellitus. At follow-up, EWL was 60.4{\%}, where 58.8{\%} achieved >50{\%} EWL and 32{\%} achieved >75{\%} EWL. 80{\%} of patients with type II diabetes achieved resolution. Total cholesterol to high density lipoprotein ratio improved from 4.5 (S.D. 1.1) mmol/L to 4.0 (S.D. 0.8) mmol/L (p=0.063). Conclusion: In Australia, initial results suggest that by an average of 10 months post-surgery, SADI-S/OADS is an effective treatment for obesity and results in a high rate of type II diabetes resolution with improvements to the lipid profile. Long-term follow-up will strengthen confidence in the efficacy of SADI-S/OADS for treating obesity in Australia.",
author = "Skye Marshall and Nova Jordaan and Jacobus Jordaan",
note = "Submitted. Awaiting outcome.",
year = "2019",
month = "8",
doi = "10.1007{\%}2Fs11695-019-04101-1",
language = "English",
volume = "29",
pages = "158",
journal = "Obesity Surgery",
issn = "0960-8923",
publisher = "Springer",
number = "S5",

}

An Australian perspective on SADI-S/OADS: Excess weight loss and comorbidity improvement. / Marshall, Skye; Jordaan, Nova; Jordaan, Jacobus.

In: Obesity Surgery, Vol. 29, No. S5, O-134, 08.2019, p. 158.

Research output: Contribution to journalMeeting AbstractResearchpeer-review

TY - JOUR

T1 - An Australian perspective on SADI-S/OADS: Excess weight loss and comorbidity improvement

AU - Marshall, Skye

AU - Jordaan, Nova

AU - Jordaan, Jacobus

N1 - Submitted. Awaiting outcome.

PY - 2019/8

Y1 - 2019/8

N2 - Background: The single anastomosis duodenal-ileal bypass with sleeve gastrectomy or one anastomosis duodenal switch (SADI-S/OADS) has been utilised as a treatment for obesity in Australia since 2016; however, the impact of SADI-S/OADS on health-related outcomes has not been reported in the Australian population. Objectives: To determine the effect of SADI-S/OADS on excess weight loss (EWL) and comorbidities in obese Australian adults. Methods: Retrospective cohort study. Adults were eligible if they attended SADI-S/OADS, with a minimum of 3-months follow-up. Results: 85 patients underwent SADI-S/OADS. Eligible patients were 44.7 (S.D. 10.9) years of age, 64.7% female, with an average follow-up of 10.7 months. At baseline the mean BMI was 47.0 (S.D. 9.1) and 30.3% had type II diabetes mellitus. At follow-up, EWL was 60.4%, where 58.8% achieved >50% EWL and 32% achieved >75% EWL. 80% of patients with type II diabetes achieved resolution. Total cholesterol to high density lipoprotein ratio improved from 4.5 (S.D. 1.1) mmol/L to 4.0 (S.D. 0.8) mmol/L (p=0.063). Conclusion: In Australia, initial results suggest that by an average of 10 months post-surgery, SADI-S/OADS is an effective treatment for obesity and results in a high rate of type II diabetes resolution with improvements to the lipid profile. Long-term follow-up will strengthen confidence in the efficacy of SADI-S/OADS for treating obesity in Australia.

AB - Background: The single anastomosis duodenal-ileal bypass with sleeve gastrectomy or one anastomosis duodenal switch (SADI-S/OADS) has been utilised as a treatment for obesity in Australia since 2016; however, the impact of SADI-S/OADS on health-related outcomes has not been reported in the Australian population. Objectives: To determine the effect of SADI-S/OADS on excess weight loss (EWL) and comorbidities in obese Australian adults. Methods: Retrospective cohort study. Adults were eligible if they attended SADI-S/OADS, with a minimum of 3-months follow-up. Results: 85 patients underwent SADI-S/OADS. Eligible patients were 44.7 (S.D. 10.9) years of age, 64.7% female, with an average follow-up of 10.7 months. At baseline the mean BMI was 47.0 (S.D. 9.1) and 30.3% had type II diabetes mellitus. At follow-up, EWL was 60.4%, where 58.8% achieved >50% EWL and 32% achieved >75% EWL. 80% of patients with type II diabetes achieved resolution. Total cholesterol to high density lipoprotein ratio improved from 4.5 (S.D. 1.1) mmol/L to 4.0 (S.D. 0.8) mmol/L (p=0.063). Conclusion: In Australia, initial results suggest that by an average of 10 months post-surgery, SADI-S/OADS is an effective treatment for obesity and results in a high rate of type II diabetes resolution with improvements to the lipid profile. Long-term follow-up will strengthen confidence in the efficacy of SADI-S/OADS for treating obesity in Australia.

U2 - 10.1007%2Fs11695-019-04101-1

DO - 10.1007%2Fs11695-019-04101-1

M3 - Meeting Abstract

VL - 29

SP - 158

JO - Obesity Surgery

JF - Obesity Surgery

SN - 0960-8923

IS - S5

M1 - O-134

ER -